Valldeoriola Francesc, Grandas Francisco, Santos-García Diego, Regidor Ignacio, Catalán María José, Arbelo José Matías, Puente Víctor, Mir Pablo, Parra Juan Carlos
Movement Disorders Unit, Neurology Department, Hospital Clínic, Carrer Villarroel, 170, 08036 Barcelona, Spain.
Neurology Department, Hospital General Universitario Gregorio Marañón, Calle del Doctor Esquerdo 46, 28007 Madrid, Spain.
Neurodegener Dis Manag. 2016 Aug;6(4):289-98. doi: 10.2217/nmt-2016-0021. Epub 2016 Jul 21.
To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease.
PATIENTS & METHODS: This was an observational, multicenter, cross-sectional, retrospective study.
Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively.
This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.
评估左旋多巴-卡比多巴肠凝胶（LCIG）对西班牙晚期帕金森病患者的长期疗效和耐受性。
这是一项观察性、多中心、横断面、回顾性研究。
分析了177例患者的数据。LCIG治疗使每日“关”期时间百分比降低（LCIG治疗前为47.6%，治疗后为16.2%），每日“开”期且无致残性异动症的时间百分比增加（分别为55.6%和21.6%）。大多数患者在步态冻结、震颤、头晕、疲劳或情绪低落方面有所改善。分别有36.2%、42.4%和43.5%的患者报告了与左旋多巴、胃造口术和技术问题相关的不良事件。
本研究证实了LCIG对晚期帕金森病患者的长期疗效和安全性。
